Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 16/20 | 0.60 |
| ▸ | LONP1 | P36776 | 11/20 | 0.60 |
| ▸ | PSMB8 | P28062 | 10/20 | 0.60 |
| ▸ | PSMB9 | P28065 | 10/20 | 0.60 |
| ▸ | PSMB6 | P28072 | 10/20 | 0.60 |
| ▸ | PSMB10 | P40306 | 10/20 | 0.60 |
| ▸ | PSMB11 | A5LHX3 | 9/20 | 0.60 |
| ▸ | PSMA7 | O14818 | 9/20 | 0.60 |
| ▸ | PSMB1 | P20618 | 9/20 | 0.60 |
| ▸ | PSMA1 | P25786 | 9/20 | 0.60 |
| ▸ | PSMA2 | P25787 | 9/20 | 0.60 |
| ▸ | PSMA3 | P25788 | 9/20 | 0.60 |
| ▸ | PSMA4 | P25789 | 9/20 | 0.60 |
| ▸ | PSMA5 | P28066 | 9/20 | 0.60 |
| ▸ | PSMB4 | P28070 | 9/20 | 0.60 |
| ▸ | PSMB3 | P49720 | 9/20 | 0.60 |
| ▸ | PSMB2 | P49721 | 9/20 | 0.60 |
| ▸ | PSMA6 | P60900 | 9/20 | 0.60 |
| ▸ | PSMA8 | Q8TAA3 | 9/20 | 0.60 |
| ▸ | PSMB7 | Q99436 | 9/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL2336540 | 0.88 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| D-Leucine SCHEMBL2338392 | 0.88 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL21955431 | 0.88 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL1041561 | 0.88 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL20496418 | 0.87 | PSMB5 (0.58) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL1406108 | 0.86 | PSMB5 (0.66) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL19712512 | 0.86 | PSMB5 (0.66) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL3202113 | 0.86 | GPR132 (0.53) | PSMB5GPR132 | |
| SCHEMBL6760909 | 0.84 | PSMB5 (0.69) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL2931152 | 0.84 | PSMB5 (0.68) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008721-B1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11667654-B2 | Process for the preparation of boronic acid esters | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2023-06-06 | — | — | US | disclosed |
| US-20220204558-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2022-06-30 | — | — | US | disclosed |
| EP-4008721-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210395301-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3385267-B1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210171574-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200369722-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200157143-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200031850-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BORONIC ACID ESTERS | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2020-01-30 | — | — | US | disclosed |
| WO-2009004350-A1 | METHODS FOR PREPARING BORTEZOMIB AND INTERMEDIATES USED IN ITS MANUFACTURE | PLIVA HRVATSKA D.O.O. (HR) | 2009-01-08 | — | — | WO | disclosed |
| EP-1756121-A2 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7109323-B2 | lyophilization of an aqueous mixture comprising a boronic add compound and a compound having at least two hydroxyl groups produces a stable composition that readily releases the boronic acid compound upon dissolution in aqueous media | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060084592-A1 | Peptide boronic acid inhibitors | TRIGEN LIMITED | 2006-04-20 | — | — | US | disclosed |
| US-20050282742-A1 | Formulation of boronic acid compounds | Government of the USA, represented by the Secretary,Dept. of Health and Human Services (US) | 2005-12-22 | — | — | US | disclosed |
| US-20050240047-A1 | contacting the boronate complex of formula with Lewis acid catalyst in presence of a coordinating ether solvent having low miscibililty in water | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005097809-A2 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20040138411-A1 | Formulation of boronic acid compounds | Government of U.S.A., represented by the Secretary Department of Health & Human Services | 2004-07-15 | — | — | US | disclosed |
| US-6699835-B2 | BORON COMPOUND FOR USE IN THE TREATMENT OF STROKE, HEART DEFECTS, INFLAMMATION, AUTOIMMUNE AND CANCER DISEASE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-02 | — | — | US | disclosed |
| US-20020188100-A1 | Formulation of boronic acid compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084592-A1 | Peptide boronic acid inhibitors | BMX, YBX1, HAX1 | PSMB5 3160/4885LONP1 3940/4885PSMB8 3518/4885 |
| US-20020188100-A1 | Formulation of boronic acid compounds | SLC10A2, BTD, SLC10A1 | PSMB5 1670/4885LONP1 4212/4885PSMB8 3710/4885 |
| US-20050282742-A1 | Formulation of boronic acid compounds | SLC10A2, BTD, SLC10A1 | PSMB5 1670/4885LONP1 4212/4885PSMB8 3710/4885 |
| US-11667654-B2 | Process for the preparation of boronic acid esters | PBRM1, BET1, MALT1 | PSMB5 275/4885LONP1 1519/4885PSMB8 1052/4885 |
| US-20220204558-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885 |
| US-20040138411-A1 | Formulation of boronic acid compounds | SLC10A2, SLC10A1, BTD | PSMB5 1172/4885LONP1 3670/4885PSMB8 3012/4885 |
| US-20210395301-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885 |
| US-20200031850-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BORONIC ACID ESTERS | BET1, PBRM1, BTD | PSMB5 163/4885LONP1 1362/4885PSMB8 706/4885 |
| US-20200157143-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885 |
| US-20050240047-A1 | contacting the boronate complex of formula with Lewis acid catalyst in presence of a coordinating ether solvent having low miscibililty in water | PSMC2, PSMC1, PSMC5 | PSMB5 35/4885LONP1 1346/4885PSMB8 29/4885 |
| US-20200369722-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885 |
| US-20210171574-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.